Program
latozinemab
Also written as “AL001”, “AL-001” and “Part 1 Blinded - AL001”.
Its studies are mostly in Frontotemporal Dementia · Macular Degeneration · Neurodegenerative Diseases · Amyotrophic Lateral Sclerosis · Alzheimer Disease, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alector | 50 open or running | phase 3since Apr 23, 2020 | Jul 12, 2018 | none ahead |
| Alzamend Neuro | 31 open or running | phase 2since Apr 27, 2022 | Apr 27, 2022 | Jul 2027phase 2 · NCT07540338 |
| Beijing Anlong Biopharmaceutical | 22 open or running | phase 2since Nov 25, 2024 | Nov 25, 2024 | none ahead |
Also a collaborator on its studies: GlaxoSmithKline.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2018First study: phase 1 study in Frontotemporal DementiaNew to AlectorAlector · NCT03636204 · 64 enrolled · United States, Canada, United Kingdom
- May 14, 2019Phase 2 study in Frontotemporal DementiaAlector · NCT03987295 · 33 enrolled · United States, Canada, Germany and more
- Apr 23, 2020Phase 3 study in Frontotemporal DementiaAlector · NCT04374136 · 119 enrolled · United States, Argentina, Australia and more
- Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisAlector · NCT05053035 · 5 enrolled · United States
- Apr 27, 2022Alzamend Neuro’s first study: phase 2 study in Alzheimer DiseaseNew to Alzamend NeuroAlzamend Neuro · NCT05363293 · 65 enrolled · United States, Canada
- Oct 18, 2023Phase 3 study in Neurodegenerative DiseasesAlector · NCT06111014 · 17 enrolled · United States, Belgium, Canada and more
- Nov 25, 2024Beijing Anlong Biopharmaceutical’s first study: phase 2 study in Wet Age-related Macular Degeneration (wAMD)New to Beijing Anlong BiopharmaceuticalBeijing Anlong Biopharmaceutical · NCT06707753 · 21 enrolled · China
- Feb 17, 2025Phase 2 study in Wet Age-related Macular Degeneration (wAMD)Beijing Anlong Biopharmaceutical · NCT06839339 · 40 planned · China
- Mar 19, 2025Phase 1 study in PharmacokineticsAlzamend Neuro · NCT06921590 · 15 enrolled · United States
- Mar 17, 2026Phase 2 study in Bipolar I DisorderAlzamend Neuro · NCT07540338 · 20 enrolled · United States
Ahead
- Jul 2027Primary completion: phase 2 study in Bipolar I DisorderAlzamend Neuro · NCT07540338
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07540338Bipolar I Disorder · United States | 2 | Active, not recruiting | Alzamend Neuro | Jul 2027 | 20 |
| NCT06921590Pharmacokinetics · United States | 1 | Completed | Alzamend Neuro | Dec 15, 2025 | 15 |
| NCT06839339Wet Age-related Macular Degeneration (wAMD) · China | 2 | Not yet recruiting | Beijing Anlong Biopharmaceutical | Sep 30, 2026 | 40 |
| NCT06707753Wet Age-related Macular Degeneration (wAMD) · China | 2 | Active, not recruiting | Beijing Anlong Biopharmaceutical | Aug 31, 2025 | 21 |
| NCT06111014Neurodegenerative Diseases · United States, Belgium, Canada and more | 3 | Terminated | Alector | Sep 1, 2025 | 17 |
| NCT05363293Alzheimer Disease · United States, Canada | 2 | Completed | Alzamend Neuro | Apr 14, 2023 | 65 |
| NCT05053035Amyotrophic Lateral Sclerosis · United States | 2 | Terminated | Alector | Oct 28, 2022 | 5 |
| NCT04374136Frontotemporal Dementia · United States, Argentina, Australia and more | 3 | Terminated | Alector | Sep 1, 2025 | 119 |
| NCT03987295Frontotemporal Dementia · United States, Canada, Germany and more | 2 | Completed | Alector | Jun 5, 2024 | 33 |
| NCT03636204Frontotemporal Dementia · United States, Canada, United Kingdom | 1 | Completed | Alector | Dec 31, 2019 | 64 |
How it is read
Names in the registry
- “AL001”, 6 entries
- “AL-001”, 2 entries
- “Part 1 Blinded - AL001”, 1 entry
- “Part 2 (OLE Treatment) - AL001”, 1 entry
- “Latozinemab”, 1 entry
Codes read as this program: AL001.
Conditions, from the studies’ own filings
- Frontotemporal Dementia, 3 studies
- Macular Degeneration, 2 studies
- Neurodegenerative Diseases, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.